Nordicus Partners (NORD) closed at $2.70 on November 12, 2026, down 9.7% from the previous close, on volume of 756 shares (30-day average 24,310).
Data as of November 12, 2026.
No press releases found.
Nordicus Partners Announces Financing and Executive Compensation Agreements
TipRanks (Tue, 10-Nov 5:27 PM ET)
Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.
Nordicus Partners trades on the NASDAQ stock market under the symbol NORD.
As of November 12, 2026, NORD stock price declined to $2.70 with 756 million shares trading.
NORD has a market cap of $52.50 million. This is considered a Micro Cap stock.
NORD support price is $2.44 and resistance is $3.54 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NORD shares will trade within this expected range on the day.
